Drug Profile

BBT 209

Alternative Names: BBT-209

Latest Information Update: 12 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shaperon
Developer Bridge Biotherapeutics; Shaperon
Class Antifibrotics
Mechanism of Action G protein-coupled receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Idiopathic pulmonary fibrosis

Most Recent Events

01 Sep 2022 Pharmacodynamics data from a non-clinical study in Idiopathic pulmonary fibrosis (IPF) was presented at the 6^thAnnual IPF Summit (IPF-2022)
18 Apr 2022 Bridg Biotherapeutics in-licenses BBT 209 from Shaperon for the development of Idiopathic pulmonary fibrosis
18 Apr 2022 Preclinical trials in Idiopathic pulmonary fibrosis in South Korea (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com